The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
